AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RHYTHM BIOSCIENCES LTD

0.105

+0.01719.32%

Volume:1.02M

Turnover:101.68K

Market Cap:37.16M

PE:-4.72

High:0.105

Open:0.093

Low:0.091

Close:0.088

52wk High:0.280

52wk Low:0.075

Shares:353.87M

Float Shares:188.31M

Volume Ratio:7.56

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.022

EPS(LYR):-0.014

ROE:-190.14%

ROA:-91.40%

PB:17.33

PE(LYR):-7.38

Loading ...

Overview Company News Filings

Rhythm Biosciences geneType PRS cancer risk test joins CancerIQ platform network

Rhythm Biosciences Ltd-Rhyo Underwriting Update

THOMSON REUTERS

Rhythm Biosciences Says Cancer Test Early Commercial Adoption Program Hits Milestone; Shares Jump 5%

MT Newswires Live

Rhythm Biosciences Says Cancer Risk Assessment Test Sale in the Philippines Constitutes First Southeast Asia Sale

MT Newswires Live

Rhythm Biosciences Activates First Commercial Blood Collection Network for Cancer Blood Test Product; Shares Up 3%

MT Newswires Live

Rhythm Biosciences Completes First Sale of Colorectal Cancer Test; Shares Up 13%

MT Newswires Live

Rhythm Biosciences Says Australian Laboratory Accreditation Body Confirms Colorectal Cancer Test Meets Standard; Shares Rise 8%

MT Newswires Live

BRIEF-Rhythm Biosciences Executes Distribution Agreement For Genetype

Rhythm Biosciences Secures Supply Deal With UK Cancer Diagnostics Company

MT Newswires Live

Rhythm Biosciences - Executes Distribution Agreement for Genetype for Southeast Asian Market With Digistain Ltd (UK)

THOMSON REUTERS

BRIEF-Rhythm Biosciences Seeks Trading Halt

Rhythm Biosciences Signs Distribution Deal With Pathology Company; Shares Up 10%

MT Newswires Live

BRIEF-Rhythm Biosciences Enters ColoSTAT Services Agreement With 4Cyte Pathology

Rhythm Biosciences Ltd - Enters Colostat Services Agreement With 4Cyte Pathology

THOMSON REUTERS

Rhythm Biosciences Enrolls First Physician Participant in Colorectal Cancer Detection Test Program; Shares Jump 9%

MT Newswires Live

BUZZ-Rhythm Biosciences set for best week in nearly 6 years

The 38% return this week takes Rhythm Biosciences' (ASX:RHY) shareholders one-year gains to 167%

Simply Wall St.

Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product

MT Newswires Live

BUZZ-Australia's Rhythm Biosciences at nearly 6-month high on multi-year supply agreement

BRIEF-Rhythm Biosciences Signs Manufacturing Agreement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/RHY.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","market":"AU","secType":"STK","nameCN":"RHYTHM BIOSCIENCES LTD","latestPrice":0.105,"timestamp":1787638320000,"preClose":0.088,"halted":0,"volume":1019920,"delay":0,"changeRate":0.1931818181818182,"nameEN":"RHYTHM BIOSCIENCES LTD","floatShares":188306561,"shares":353866857,"eps":-0.022243,"marketStatus":"Closed","change":0.017,"latestTime":"08-25 16:12:00 AEST","open":0.093,"high":0.105,"low":0.091,"amount":101682,"amplitude":0.159091,"askPrice":0.11,"askSize":33695,"bidPrice":0.097,"bidSize":32355,"shortable":3,"etf":0,"ttmEps":-0.022243,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.088,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":7.56109,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RHY.AU","preClose":0.088,"auctionPrice":0.105,"auctionVolume":1275,"auctionTime":1787638177771,"referencePrice":0.105,"referenceTime":1787648400864,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638177771}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","floatShares":188306561,"roa":"-91.40%","roe":"-190.14%","lyrEps":-0.014222,"volumeRatio":7.56109,"shares":353866857,"dividePrice":0,"high":0.105,"amplitude":0.159091,"preClose":0.088,"low":0.091,"week52Low":0.075,"pbRate":"17.33","psRate":"22.55","week52High":0.28,"institutionHeld":0,"latestPrice":0.105,"committee":-0.020288,"eps":-0.022243,"divideRate":0,"volume":1019920,"delay":0,"ttmEps":-0.022243,"open":0.093,"prevYearClose":0.135,"prevWeekClose":0.088,"prevMonthClose":0.079,"prevQuarterClose":0.091,"fiveDayClose":0.085,"twentyDayClose":0.079,"sixtyDayClose":0.105,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHY.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-07-27","symbol":"RHY.AU","type":"split","dateTimestamp":1595772000000,"forFactor":875,"toFactor":1000,"ratio":0.875}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHY.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHY.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640154700","title":"Rhythm Biosciences geneType PRS cancer risk test joins CancerIQ platform network","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154700","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640154700?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:37","pubTimestamp":1780573041,"startTime":"0","endTime":"0","summary":"CancerIQ added Rhythm Biosciences’ geneType Cancer Risk Assessment to its platform, expanding ordering access across a network of more than 60 health systems.The test combines a polygenic risk score with clinical and family history to produce 5-year and lifetime risk estimates across six cancers.The rollout targets patients with prior hereditary cancer testing or risk not fully explained by traditional models, supporting more personalized screening decisions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL4fRhMm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630378848","title":"Rhythm Biosciences Ltd-Rhyo Underwriting Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2630378848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630378848?lang=en_us&edition=fundamental","pubTime":"2026-04-28 15:24","pubTimestamp":1777361091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUE59VSBT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623606153","title":"Rhythm Biosciences Says Cancer Test Early Commercial Adoption Program Hits Milestone; Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623606153","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623606153?lang=en_us&edition=fundamental","pubTime":"2026-03-30 11:23","pubTimestamp":1774841006,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that its ColoSTAT Access program, which provides a pathway for the early commercial adoption of its ColoSTAT cancer test reached 10 participating clinician sites across Victoria, New South Wales, and Queensland, according to a Monday Australian bourse filing.Meanwhile, an additional 40 blood collection sites were activated as part of its commercial network rollout strategy with its partner 4Cyte Pathology, bringing the total to 78 activated commercial collection centers, per the filing.The company's shares rose past 5% in recent trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837878","title":"Rhythm Biosciences Says Cancer Risk Assessment Test Sale in the Philippines Constitutes First Southeast Asia Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837878","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622837878?lang=en_us&edition=fundamental","pubTime":"2026-03-26 07:44","pubTimestamp":1774482258,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  made a sale of its geneType cancer risk assessment test in Manila, Philippines, the first sale in Southeast Asia, according to a Thursday Australian bourse filing.The firm partnered with Digistain in the region earlier in March. The Digistain team effectively completed the initial commercial pilot and will now scale sales across the Philippines before setting up pilots in other Southeast Asian markets.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620077024","title":"Rhythm Biosciences Activates First Commercial Blood Collection Network for Cancer Blood Test Product; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620077024","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620077024?lang=en_us&edition=fundamental","pubTime":"2026-03-18 09:23","pubTimestamp":1773796980,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said it successfully activated its first commercial blood collection network of clinics across major cities, enabling the scaling of cancer blood test, ColoSTAT's commercial testing services, according to a Wednesday Australian bourse filing.The ColoSTAT test is a blood-based test for the detection of colorectal cancer.4Cyte Pathology activated an initial network of 38 blood collection sites across major cities in Queensland, New South Wales, and Victoria, enabling clinician referral and patient access to ColoSTAT testing through an established clinician pathway, the filing added.Clinicians within designated 4Cyte Pathology clinics are being onboarded to provide referrals for ColoSTAT testing, with additional collection sites planned as part of the ongoing commercial rollout, the filing added.The company said immediate scale-up can now proceed directly with physicians and through the ColoSTAT access program using a validated commercial and logistical pathway.The com","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618960171","title":"Rhythm Biosciences Completes First Sale of Colorectal Cancer Test; Shares Up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618960171","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618960171?lang=en_us&edition=fundamental","pubTime":"2026-03-11 07:58","pubTimestamp":1773187133,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  completed the first sale of the blood-based ColoSTAT colorectal cancer test, according to a Wednesday filing with the Australian bourse.The company will scale up test volumes directly with physicians and through its ColoSTAT Access Program, the filing said.Shares rose nearly 13% in morning trade Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618930616","title":"Rhythm Biosciences Says Australian Laboratory Accreditation Body Confirms Colorectal Cancer Test Meets Standard; Shares Rise 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618930616","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618930616?lang=en_us&edition=fundamental","pubTime":"2026-03-09 11:22","pubTimestamp":1773026565,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said the National Association of Testing Authorities confirmed that its ColoSTAT blood-based colorectal cancer test satisfies all applicable technical and quality requirements under the ISO 15189:2022 standard, according to a Monday Australian bourse filing.The test's validation and intended clinical application were reviewed in accordance with the National Pathology Accreditation Advisory Council requirements. ColoSTAT was formally listed within the accredited scope of Rhythm's laboratory in Parkville, Victoria.Its shares jumped 8% in recent trading on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU","BK7124","XAO.AU","XKO.AU","BK4124","SMP","XJO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616306782","title":"BRIEF-Rhythm Biosciences Executes Distribution Agreement For Genetype","url":"https://stock-news.laohu8.com/highlight/detail?id=2616306782","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616306782?lang=en_us&edition=fundamental","pubTime":"2026-03-04 09:09","pubTimestamp":1772586573,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Executes Distribution Agreement For GenetypeMarch 4 (Reuters) - Rhythm Biosciences Ltd RHY.AX:EXECUTES DISTRIBUTION AGREEMENT FOR GENETYPE FOR SOUTHEAST ASIAN MARKET WITH DIGISTAIN LTD (UK)Further company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZR17M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616306119","title":"Rhythm Biosciences Secures Supply Deal With UK Cancer Diagnostics Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2616306119","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616306119?lang=en_us&edition=fundamental","pubTime":"2026-03-04 09:00","pubTimestamp":1772586033,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  secured an agreement with UK-incorporated cancer diagnostics company Digistain for the supply of its geneType genetic test portfolio, according to a Wednesday filing with the Australian bourse.The deal grants Digistain the right to market and distribute the genetic test portfolio in Southeast Asia for an initial 12-month term, with renewal provisions supporting scalable expansion, the filing said.Revenue is generated per test as samples are processed and reported, with invoicing done monthly and 30-day payment terms, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616372197","title":"Rhythm Biosciences - Executes Distribution Agreement for Genetype for Southeast Asian Market With Digistain Ltd (UK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616372197","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616372197?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:58","pubTimestamp":1772575125,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR17M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613274488","title":"BRIEF-Rhythm Biosciences Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2613274488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613274488?lang=en_us&edition=fundamental","pubTime":"2026-02-23 06:56","pubTimestamp":1771800998,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Seeks Trading Halt Feb 23 (Reuters) - Rhythm Biosciences Ltd RHY.AX:SEEKS TRADING HALT PENDING UNDERWRITING AGREEMENT ANNOUNCEMENTFurther company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nFWN3ZG0TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612943981","title":"Rhythm Biosciences Signs Distribution Deal With Pathology Company; Shares Up 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612943981","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612943981?lang=en_us&edition=fundamental","pubTime":"2026-02-17 10:50","pubTimestamp":1771296649,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  entered into a distribution service agreement with 4Cyte Pathology for its ColoSTAT diagnostic test for the detection of colorectal cancer, according to a Tuesday filing with the Australian bourse.4Cyte will integrate ColoSTAT into its clinical ordering system across its network of patient collection centers in New South Wales, Victoria, and Queensland, with no minimum volume commitments or upfront payments under the deal, the filing said.The deal has an initial three-year term and an option for a two-year extension by mutual agreement, per the filing.Rhythm Biosciences shares rose nearly 10% in afternoon trade on Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612884438","title":"BRIEF-Rhythm Biosciences Enters ColoSTAT Services Agreement With 4Cyte Pathology","url":"https://stock-news.laohu8.com/highlight/detail?id=2612884438","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612884438?lang=en_us&edition=fundamental","pubTime":"2026-02-17 06:21","pubTimestamp":1771280464,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Enters ColoSTAT Services Agreement With 4Cyte PathologyFeb 17 (Reuters) - Rhythm Biosciences Ltd RHY.AX:ENTERS COLOSTAT SERVICES AGREEMENT WITH 4CYTE PATHOLOGYFurther company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nFWN3ZC0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612696480","title":"Rhythm Biosciences Ltd -  Enters Colostat Services Agreement With 4Cyte Pathology","url":"https://stock-news.laohu8.com/highlight/detail?id=2612696480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612696480?lang=en_us&edition=fundamental","pubTime":"2026-02-17 05:39","pubTimestamp":1771277998,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nFWN3ZC0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610606565","title":"Rhythm Biosciences Enrolls First Physician Participant in Colorectal Cancer Detection Test Program; Shares Jump 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610606565","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610606565?lang=en_us&edition=fundamental","pubTime":"2026-02-11 10:03","pubTimestamp":1770775389,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  enrolled the first physician participant in its ColoSTAT Access Program, a commercial deployment framework for its blood-based test for the detection of colorectal cancer, according to a Wednesday Australian bourse filing.Under the program, participating clinicians receive an initial allocation of ColoSTAT tests at no cost and continued use of the test after the initial allocation is expected to be on a paid basis, the filing said. The program will be capped at 20 participants in Australia.Rhythm Biosciences' shares jumped nearly 9% in recent trading on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609290553","title":"BUZZ-Rhythm Biosciences set for best week in nearly 6 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2609290553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609290553?lang=en_us&edition=fundamental","pubTime":"2026-02-06 12:51","pubTimestamp":1770353471,"startTime":"0","endTime":"0","summary":"BUZZ-Rhythm Biosciences set for best week in nearly 6 years** Shares of Australia's Biosciences RHY.AX rise as much as 19.2% to A$0.28, their highest level since October 11, 2023** On track for best week since late-March 2020, gaining 79.3% this week** The medical diagnostics tech firm secured a multi-year commercial supply agreement executed with U.S.-based Quansys Biosciences for ColoSTAT reagent kit manufacturing on Tuesday** About 3.1 million shares change hands, 3.4 times the 30-day avg** Up 92.6% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609153073","title":"The 38% return this week takes Rhythm Biosciences' (ASX:RHY) shareholders one-year gains to 167%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609153073","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609153073?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:16","pubTimestamp":1770333403,"startTime":"0","endTime":"0","summary":"Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-rhy/rhythm-biosciences-shares/news/the-38-return-this-week-takes-rhythm-biosciences-asxrhy-shar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-rhy/rhythm-biosciences-shares/news/the-38-return-this-week-takes-rhythm-biosciences-asxrhy-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608479418","title":"Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2608479418","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608479418?lang=en_us&edition=fundamental","pubTime":"2026-02-03 15:06","pubTimestamp":1770102389,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608281217","title":"BUZZ-Australia's Rhythm Biosciences at nearly 6-month high on multi-year supply agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608281217","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608281217?lang=en_us&edition=fundamental","pubTime":"2026-02-03 09:33","pubTimestamp":1770082415,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Rhythm Biosciences at nearly 6-month high on multi-year supply agreement** Shares of Rhythm Biosciences RHY.AX rise as much as 33.3% to A$0.20, their highest level since August 6, 2025** The medical diagnostics tech firm secures a multi-year commercial supply agreement executed with U.S.-based Quansys Biosciences for ColoSTAT reagent kit manufacturing** Agreement provides scalable manufacturing capacity to support ColoSTAT Access Program and commercial rollout, adds co** About 1.5 million shares change hands, 2.3x the 30-day average** YTD, stock up 37% year, including the day's move  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL4N3YZ039:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608814042","title":"BRIEF-Rhythm Biosciences Signs Manufacturing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608814042","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608814042?lang=en_us&edition=fundamental","pubTime":"2026-02-03 09:17","pubTimestamp":1770081464,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Signs Manufacturing AgreementFeb 3 (Reuters) - Rhythm Biosciences Ltd RHY.AX:RHYTHM BIOSCIENCES SIGNS MANUFACTURING AGREEMENTMULTI-YEAR COMMERCIAL SUPPLY AGREEMENT EXECUTED WI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YY1P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}